Distribution of molecular subtypes was as follows: luminal A in 30 cases (27.8%), luminal B/HER2− in 19 cases (17.6%), luminal B/HER2+ in 10 cases (9.3%), HER2+ non-luminal (HER2+) in 20 cases (18.5%), and triple-negative breast cancer (TNBC) in 29 cases (26.8%). The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.